Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers
NCT ID: NCT00813670
Last Updated: 2009-09-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
64 participants
INTERVENTIONAL
2008-11-30
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The effect of food on the pharmacokinetics of XPF-001 will also be studied.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162
NCT01691274
Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers.
NCT05628116
A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649
NCT02151617
A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Following A Single Dose Of PF-04995274 In Healthy Adult Volunteers
NCT01091272
Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers
NCT02228395
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: Single dose of XPF-001
XPF-001
Single oral dose, or 6 days of repeated oral doses.
Cohort 2: Single dose of XPF-001
XPF-001
Single oral dose, or 6 days of repeated oral doses.
Cohort 3: Single dose of XPF-001
XPF-001
Single oral dose, or 6 days of repeated oral doses.
Cohort 4: Single dose of XPF-001
XPF-001
Single oral dose, or 6 days of repeated oral doses.
Cohort 5: Single dose of XPF-001
XPF-001
Single oral dose, or 6 days of repeated oral doses.
Cohort A: Repeated doses of XPF-001
XPF-001
Single oral dose, or 6 days of repeated oral doses.
Cohort B: Repeated doses of XPF-001
XPF-001
Single oral dose, or 6 days of repeated oral doses.
Cohort C: Repeated doses of XPF-001
XPF-001
Single oral dose, or 6 days of repeated oral doses.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
XPF-001
Single oral dose, or 6 days of repeated oral doses.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subjects who have participated in and investigational drug trial within 60 days of admission.
* Subjects who have used tobacco or nictoine products in the 1 month prior to admission
* Females who are pregnant or breastfeeding
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xenon Pharmaceuticals Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xenon
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard Larouche, MD
Role: PRINCIPAL_INVESTIGATOR
Anapharm
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anapharm
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XPF-001-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.